Joan MassaguÃ© SolÃ©

List of Publications by Year
in descending order

253 papers	121,818 citations	191 150 h-index	640 256 g-index
269 all docs	269 docs citations	269 times ranked	84663 citing authors

#	Article	IF	Citations
1	Mechanisms of TGF-Î² Signaling from Cell Membrane to the Nucleus. Cell, 2003, 113, 685-700.	13.5	5,290
2	TGF-Î² SIGNAL TRANSDUCTION. Annual Review of Biochemistry, 1998, 67, 753-791.	5.0	4,586
3	Cancer Metastasis: Building a Framework. Cell, 2006, 127, 679-695.	13.5	3,702
4	TGFÎ² in Cancer. Cell, 2008, 134, 215-230.	13.5	3,312
5	The Transforming Growth Factor-beta Family. Annual Review of Cell Biology, 1990, 6, 597-641.	26.0	3,045
6	TGFÎ² signalling in context. Nature Reviews Molecular Cell Biology, 2012, 13, 616-630.	16.1	2,619
7	Genes that mediate breast cancer metastasis to lung. Nature, 2005, 436, 518-524.	13.7	2,581
8	A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3, 537-549.	7.7	2,325
9	Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer, 2009, 9, 274-284.	12.8	2,287
10	TGFÎ² Signaling in Growth Control, Cancer, and Heritable Disorders. Cell, 2000, 103, 295-309.	13.5	2,239
11	Mechanism of activation of the TGF-Î² receptor. Nature, 1994, 370, 341-347.	13.7	2,237
12	Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 1994, 78, 59-66.	13.5	2,065
13	Smad transcription factors. Genes and Development, 2005, 19, 2783-2810.	2.7	2,063
14	NEW EMBO MEMBERS REVIEW: Transcriptional control by the TGF-beta/Smad signaling system. EMBO Journal, 2000, 19, 1745-1754.	3.5	1,781
15	How cells read TGF-Î² signals. Nature Reviews Molecular Cell Biology, 2000, 1, 169-178.	16.1	1,745
16	Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 2008, 451, 147-152.	13.7	1,743
17	Genes that mediate breast cancer metastasis to the brain. Nature, 2009, 459, 1005-1009.	13.7	1,587
18	Metastatic colonization by circulating tumour cells. Nature, 2016, 529, 298-306.	13.7	1,498

#	Article	IF	Citations
19	Cytostatic and apoptotic actions of TGF-Î² in homeostasis and cancer. Nature Reviews Cancer, 2003, 3, 807-820.	12.8	1,486
20	TGFÎ² signals through a heteromeric protein kinase receptor complex. Cell, 1992, 71, 1003-1014.	13.5	1,465
21	Controlling TGF-beta signaling. Genes and Development, 2000, 14, 627-44.	2.7	1,386
22	Controlling TGF-Î² signaling. Genes and Development, 2000, 14, 627-644.	2.7	1,384
23	Epithelial-Mesenchymal Transitions. Cell, 2004, 118, 277-279.	13.5	1,369
24	Transforming Growth Factor-Î² Signaling in Immunity and Cancer. Immunity, 2019, 50, 924-940.	6.6	1,360
25	Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature, 1995, 376, 313-320.	13.7	1,355
26	Guidelines and definitions for research on epithelialâ€"mesenchymal transition. Nature Reviews Molecular Cell Biology, 2020, 21, 341-352.	16.1	1,195
27	Tumor Self-Seeding by Circulating Cancer Cells. Cell, 2009, 139, 1315-1326.	13.5	1,182
28	G1 cell-cycle control and cancer. Nature, 2004, 432, 298-306.	13.7	1,082
29	TGF-Î² directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 2005, 8, 369-380.	7.7	1,057
30	Crystal Structure of a Smad MH1 Domain Bound to DNA. Cell, 1998, 94, 585-594.	13.5	929
31	Molecular Basis of Metastasis. New England Journal of Medicine, 2008, 359, 2814-2823.	13.9	929
32	A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis. Cell, 2012, 150, 165-178.	13.5	913
33	Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 1994, 372, 570-573.	13.7	911
34	Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. Cell, 2004, 117, 211-223.	13.5	903
35	TGF-Î² signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigation, 1999, 103, 197-206.	3.9	882
36	Dependency of Colorectal Cancer on a TGF-Î²-Driven Program in Stromal Cells for Metastasis Initiation. Cancer Cell, 2012, 22, 571-584.	7.7	881

#	ARTICLE	IF	CITATIONS
37	Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin Aâ€“Cdk2 complex. Nature, 1996, 382, 325-331.	13.7	880
38	Partnership between DPC4 and SMAD proteins in TGF-Î² signalling pathways. Nature, 1996, 383, 832-836.	13.7	871
39	TGFÎ² Signaling: Receptors, Transducers, and Mad Proteins. Cell, 1996, 85, 947-950.	13.5	860
40	TGFÎ² Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4. Cell, 2008, 133, 66-77.	13.5	852
41	Betaglycan presents ligand to the TGFÎ² signaling receptor. Cell, 1993, 73, 1435-1444.	13.5	851
42	Growth inhibition by TGF-Î² linked to suppression of retinoblastoma protein phosphorylation. Cell, 1990, 62, 175-185.	13.5	791
43	Inhibition of transforming growth factor-Î²/SMAD signalling by the interferon-Î³/STAT pathway. Nature, 1999, 397, 710-713.	13.7	770
44	The TGF-Î² family of growth and differentiation factors. Cell, 1987, 49, 437-438.	13.5	743
45	Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 1994, 79, 487-496.	13.5	741
46	Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Medicine, 2011, 17, 867-874.	15.2	740
47	Roles of TGFÎ² in metastasis. Cell Research, 2009, 19, 89-102.	5.7	739
48	Genetic determinants of cancer metastasis. Nature Reviews Genetics, 2007, 8, 341-352.	7.7	716
49	The transforming growth factor-Î² system, a complex pattern of cross-reactive ligands and receptors. Cell, 1987, 48, 409-415.	13.5	715
50	Receptors for the TGF-Î² family. Cell, 1992, 69, 1067-1070.	13.5	704
51	Carcinomaâ€“astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature, 2016, 533, 493-498.	13.7	677
52	Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis. Cell, 2014, 156, 1002-1016.	13.5	672
53	The logic of TGFÎ² signaling. FEBS Letters, 2006, 580, 2811-2820.	1.3	657
54	Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-Î² receptor system. Cell, 1991, 67, 785-795.	13.5	653

#	Article	IF	Citations
55	Membrane-Anchored Growth Factors. Annual Review of Biochemistry, 1993, 62, 515-541.	5.0	641
56	A human Mad protein acting as a BMP-regulated transcriptional activator. Nature, 1996, 381, 620-623.	13.7	639
57	Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 2007, 446, 765-770.	13.7	629
58	Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-Î² Pathways. Cell, 2009, 139, 757-769.	13.5	627
59	Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 2002, 419, 729-734.	13.7	618
60	Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals. Cancer Cell, 2009, 16, 67-78.	7.7	609
61	Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. Journal of Clinical Investigation, 2005, 115, 44-55.	3.9	606
62	Metastatic Stem Cells: Sources, Niches, and Vital Pathways. Cell Stem Cell, 2014, 14, 306-321.	5.2	591
63	Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell, 2016, 165, 45-60.	13.5	583
64	The TGF-Î² family and its composite receptors. Trends in Cell Biology, 1994, 4, 172-178.	3.6	557
65	Contextual determinants of TGFÎ² action in development, immunity and cancer. Nature Reviews Molecular Cell Biology, 2018, 19, 419-435.	16.1	557
66	Beyond tumorigenesis: cancer stem cells in metastasis. Cell Research, 2007, 17, 3-14.	5.7	551
67	WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis. Cell, 2009, 138, 51-62.	13.5	532
68	Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature, 1995, 375, 159-161.	13.7	530
69	A Smad Transcriptional Corepressor. Cell, 1999, 97, 29-39.	13.5	523
70	Repression of p15INK4b expression by Myc through association with Miz-1. Nature Cell Biology, 2001, 3, 392-399.	4.6	504
71	Novel activin receptors: Distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell, 1992, 68, 97-108.	13.5	500
72	Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13909-13914.	3.3	500

#	Article	IF	Citations
73	A Self-Enabling TGFÎ² Response Coupled to Stress Signaling. Molecular Cell, 2003, 11, 915-926.	4.5	495
74	Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs. Cancer Cell, 2011, 20, 538-549.	7.7	493
75	TGF-Î² Tumor Suppression through a Lethal EMT. Cell, 2016, 164, 1015-1030.	13.5	488
76	The TGF-Î± precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. Cell, 1989, 56, 495-506.	13.5	469
77	Origins of Metastatic Traits. Cancer Cell, 2013, 24, 410-421.	7.7	457
78	SMADs: mediators and regulators of TGF-Î² signaling. Current Opinion in Genetics and Development, 1998, 8, 103-111.	1.5	450
79	TGFÎ² influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nature Cell Biology, 2001, 3, 400-408.	4.6	448
80	Targeting metastatic cancer. Nature Medicine, 2021, 27, 34-44.	15.2	447
81	VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging Î±4Î²1-Positive Osteoclast Progenitors. Cancer Cell, 2011, 20, 701-714.	7.7	445
82	E2F4/5 and p107 as Smad Cofactors Linking the TGFÎ² Receptor to c-myc Repression. Cell, 2002, 110, 19-32.	13.5	443
83	A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature, 1997, 388, 87-93.	13.7	436
84	Surviving at a Distance: Organ-Specific Metastasis. Trends in Cancer, 2015, 1, 76-91.	3.8	419
85	Crystal Structure of the Cytoplasmic Domain of the Type I TGF Î² Receptor in Complex with FKBP12. Cell, 1999, 96, 425-436.	13.5	415
86	Transforming growth factor Î² signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8430-8435.	3.3	409
87	Two forms of transforming growth factor-Î² distinguished by multipotential haematopoietic progenitor cells. Nature, 1987, 329, 539-541.	13.7	400
88	OAZ Uses Distinct DNA- and Protein-Binding Zinc Fingers in Separate BMP-Smad and Olf Signaling Pathways. Cell, 2000, 100, 229-240.	13.5	399
89	Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 2015, 520, 368-372.	13.7	389
90	Balancing BMP Signaling through Integrated Inputs into the Smad1 Linker. Molecular Cell, 2007, 25, 441-454.	4.5	381

#	Article	IF	Citations
91	Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors. Journal of Biological Chemistry, 1996, 271, 11376-11382.	1.6	371
92	The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. Nature, 1993, 365, 644-649.	13.7	368
93	Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nature Genetics, 2000, 25, 205-208.	9.4	368
94	Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma. Cell, 2013, 154, 1060-1073.	13.5	359
95	Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-Î² in cells lacking the CDK inhibitor p15. Nature, 1997, 387, 417-422.	13.7	356
96	The TGFÎ² Receptor Activation Process. Molecular Cell, 2001, 8, 671-682.	4.5	346
97	Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature, 1997, 388, 82-87.	13.7	345
98	Characterization and Cloning of a Receptor for BMP-2 and BMP-4 from NIH 3T3 Cells. Molecular and Cellular Biology, 1994, 14, 5961-5974.	1.1	337
99	Hematopoiesis Controlled by Distinct TIF1Î³ and Smad4 Branches of the TGFÎ² Pathway. Cell, 2006, 125, 929-941.	13.5	335
100	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
101	Lung metastasis genes couple breast tumor size and metastatic spread. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6740-6745.	3.3	331
102	Is cancer a disease of self-seeding?. Nature Medicine, 2006, 12, 875-878.	15.2	329
103	Mechanism of TGFÎ² receptor inhibition by FKBP12. EMBO Journal, 1997, 16, 3866-3876.	3.5	322
104	Ubiquitin-dependent degradation of TGF-Î²-activated Smad2. Nature Cell Biology, 1999, 1, 472-478.	4.6	321
105	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	15.2	320
106	Characterization and relationship of dpp receptors encoded by the saxophone and thick veins genes in Drosophila. Cell, 1994, 78, 251-261.	13.5	317
107	Adapting a transforming growth factor Î²â€"related tumor protection strategy to enhance antitumor immunity. Blood, 2002, 99, 3179-3187.	0.6	310
108	Physical and Functional Interaction of SMADs and p300/CBP. Journal of Biological Chemistry, 1998, 273, 22865-22868.	1.6	307

#	Article	IF	Citations
109	Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor Â growth arrest program. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 992-999.	3.3	307
110	Ubiquitin Ligase Nedd4L Targets Activated Smad2/3 to Limit TGF-Î² Signaling. Molecular Cell, 2009, 36, 457-468.	4.5	306
111	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role forÂcathepsin S. Nature Cell Biology, 2014, 16, 876-888.	4.6	300
112	Structural determinants of Smad function in TGF-Î² signaling. Trends in Biochemical Sciences, 2015, 40, 296-308.	3.7	297
113	Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. Journal of Cell Biology, 2003, 162, 1089-1098.	2.3	292
114	Structural Basis of Smad2 Recognition by the Smad Anchor for Receptor Activation. Science, 2000, 287, 92-97.	6.0	276
115	Distinct Altered Patterns of p27KIP1 Gene Expression in Benign Prostatic Hyperplasia and Prostatic Carcinoma. Journal of the National Cancer Institute, 1998, 90, 1284-1291.	3.0	275
116	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nature Medicine, 2020, 26, 259-269.	15.2	274
117	TGF-Î² receptors and actions. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1222, 71-80.	1.9	273
118	Crystal Structure of a Phosphorylated Smad2. Molecular Cell, 2001, 8, 1277-1289.	4.5	271
119	TGF-Î² orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature, 2020, 577, 566-571.	13.7	271
120	Drosophila Dpp signaling is mediated by the punt gene product: A dual ligand-binding type II receptor of the TGFÎ² receptor family. Cell, 1995, 80, 899-908.	13.5	269
121	Identification of two bone morphogenetic protein type I receptors in Drosophila and evidence that Brk25D is a decapentaplegic receptor. Cell, 1994, 78, 239-250.	13.5	268
122	Clinical implications of cancer self-seeding. Nature Reviews Clinical Oncology, 2011, 8, 369-377.	12.5	266
123	ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes and Development, 2009, 23, 1882-1894.	2.7	264
124	Direct Binding of Smad1 and Smad4 to Two Distinct Motifs Mediates Bone Morphogenetic Protein-specific Transcriptional Activation ofId1 Gene. Journal of Biological Chemistry, 2002, 277, 3176-3185.	1.6	260
125	C/EBPÎ² at the core of the TGFÎ² cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell, 2006, 10, 203-214.	7.7	259
126	A Poised Chromatin Platform for TGF-Î² Access to Master Regulators. Cell, 2011, 147, 1511-1524.	13.5	251

#	Article	IF	Citations
127	Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4. Journal of Biological Chemistry, 1997, 272, 25863-25872.	1.6	249
128	Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine, 2011, 3, 75ra25.	5.8	242
129	Nucleocytoplasmic shuttling of signal transducers. Nature Reviews Molecular Cell Biology, 2004, 5, 209-219.	16.1	240
130	<i>ID</i> genes mediate tumor reinitiation during breast cancer lung metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19506-19511.	3.3	238
131	Smad2 Nucleocytoplasmic Shuttling by Nucleoporins CAN/Nup214 and Nup153 Feeds TGFÎ² Signaling Complexes in the Cytoplasm and Nucleus. Molecular Cell, 2002, 10, 271-282.	4.5	229
132	Role of transforming growth factor-Î² in chondrogenic pattern formation in the embryonic limb: Stimulation of mesenchymal condensation and fibronectin gene expression by exogenous TGF-Î² and evidence for endogenous TGF-Î²-like activity. Developmental Biology, 1991, 145, 99-109.	0.9	223
133	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
134	Transforming growth factor Â-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15231-15236.	3.3	221
135	A FoxO-Smad synexpression group in human keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12747-12752.	3.3	221
136	Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell, 2017, 168, 1101-1113.e13.	13.5	219
137	TGF-? Receptors and TGF-? Binding Proteoglycans: Recent Progress in Identifying Their Functional Properties. Annals of the New York Academy of Sciences, 1990, 593, 59-72.	1.8	218
138	A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes and Development, 2011, 25, 1275-1288.	2.7	207
139	TGF-Î²-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition. Cell Reports, 2013, 5, 1228-1242.	2.9	205
140	Identification and expression of two forms of the human transforming growth factor-Î²-binding protein endoglin with distinct cytoplasmic regions. European Journal of Immunology, 1993, 23, 2340-2345.	1.6	201
141	Integration of Smad and MAPK pathways: a link and a linker revisited. Genes and Development, 2003, 17, 2993-2997.	2.7	201
142	Smad1 Recognition and Activation by the ALK1 Group of Transforming Growth Factor-Î² Family Receptors. Journal of Biological Chemistry, 1999, 274, 3672-3677.	1.6	200
143	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes and Development, 2011, 25, 226-231.	2.7	193
144	Human Platelet-Derived Transforming Growth Factor-<i>Î²</i>Stimulates Parameters of Bone Growth in Fetal Rat Calvariae*. Endocrinology, 1986, 119, 2306-2312.	1.4	192

#	Article	IF	Citations
145	Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nature Cell Biology, 2018, 20, 966-978.	4.6	186
146	Nomenclature: Vertebrate Mediators of TGFÎ² Family Signals. Cell, 1996, 87, 173.	13.5	177
147	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine, 2013, 19, 50-56.	15.2	174
148	Multiple Modes of Repression by the Smad Transcriptional Corepressor TGIF. Journal of Biological Chemistry, 1999, 274, 37105-37110.	1.6	170
149	Glycogen synthase: A new activity ratio assay expressing a high sensitivity to the phosphorylation state. FEBS Letters, 1979, 106, 284-288.	1.3	168
150	Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chemical Biology, 2007, 3, 498-507.	3.9	156
151	TGF-Î² singaling and cancer: structural and functional consequences of mutations in Smads. Trends in Molecular Medicine, 1998, 4, 257-262.	2.6	153
152	Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO Journal, 2001, 20, 128-136.	3.5	147
153	Dephosphorylation of the Linker Regions of Smad1 and Smad2/3 by Small C-terminal Domain Phosphatases Has Distinct Outcomes for Bone Morphogenetic Protein and Transforming Growth Factor-Î² Pathways. Journal of Biological Chemistry, 2006, 281, 40412-40419.	1.6	147
154	Engagement of Bone Morphogenetic Protein Type IB Receptor and Smad1 Signaling by Anti-MÃ¼llerian Hormone and Its Type II Receptor. Journal of Biological Chemistry, 2000, 275, 27973-27978.	1.6	144
155	The nuclear import function of Smad2 is masked by SARA and unmasked by TGFb-dependent phosphorylation. Nature Cell Biology, 2000, 2, 559-562.	4.6	138
156	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nature Cancer, 2020, 1, 28-45.	5.7	137
157	The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGFÎ± into soluble growth factor. Cell, 1992, 71, 1157-1165.	13.5	136
158	Smad4/DPC4 Silencing and Hyperactive Ras Jointly Disrupt Transforming Growth Factor-Î² Antiproliferative Responses in Colon Cancer Cells. Journal of Biological Chemistry, 1999, 274, 33637-33643.	1.6	134
159	Metastasis-Initiating Cells and Ecosystems. Cancer Discovery, 2021, 11, 971-994.	7.7	134
160	TGFâ€Î² control of stem cell differentiation genes. FEBS Letters, 2012, 586, 1953-1958.	1.3	133
161	[17] Identification of receptor for type-Î² transforming growth factor. Methods in Enzymology, 1987, 146, 174-195.	0.4	130
162	Mammalian anti proliferative signals and their targets. Current Opinion in Genetics and Development, 1995, 5, 91-96.	1.5	123

#	Article	IF	Citations
163	Sorting Out Breast-Cancer Gene Signatures. New England Journal of Medicine, 2007, 356, 294-297.	13.9	121
164	Molecular Pathways: VCAM-1 as a Potential Therapeutic Target in Metastasis. Clinical Cancer Research, 2012, 18, 5520-5525.	3.2	121
165	The p53 Family Coordinates Wnt and Nodal Inputs in Mesendodermal Differentiation of Embryonic Stem Cells. Cell Stem Cell, 2017, 20, 70-86.	5.2	121
166	Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. Clinical Breast Cancer, 2011, 11, 306-311.	1.1	118
167	Unique players in the BMP pathway: Small C-terminal domain phosphatases dephosphorylate Smad1 to attenuate BMP signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11940-11945.	3.3	117
168	Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. ELife, 2014, 3, .	2.8	115
169	TGF-Î² receptors. Molecular Reproduction and Development, 1992, 32, 99-104.	1.0	113
170	Role of the Juxtamembrane Domains of the Transforming Growth Factor-Î± Precursor and the Î²-Amyloid Precursor Protein in Regulated Ectodomain Shedding. Journal of Biological Chemistry, 1997, 272, 17160-17165.	1.6	104
171	Carboxy-terminally truncated Gli3 proteins associate with Smads. Nature Genetics, 1998, 20, 325-326.	9.4	104
172	Modeling metastasis in the mouse. Current Opinion in Pharmacology, 2010, 10, 571-577.	1.7	104
173	Characterization of high molecular weight transforming growth factor .alpha. produced by rat hepatocellular carcinoma cells. Biochemistry, 1988, 27, 6487-6494.	1.2	103
174	Genome-wide Impact of the BRG1 SWI/SNF Chromatin Remodeler on the Transforming Growth Factor Î² Transcriptional Program. Journal of Biological Chemistry, 2008, 283, 1146-1155.	1.6	103
175	TGF-Î² Inhibition and Immunotherapy: Checkmate. Immunity, 2018, 48, 626-628.	6.6	103
176	Distinct Oligomeric States of SMAD Proteins in the Transforming Growth Factor-Î² Pathway. Journal of Biological Chemistry, 2000, 275, 40710-40717.	1.6	102
177	Distinct Domain Utilization by Smad3 and Smad4 for Nucleoporin Interaction and Nuclear Import. Journal of Biological Chemistry, 2003, 278, 42569-42577.	1.6	102
178	Integral membrane glycoprotein properties of the prohormone pro-transforming growth factor-Î±. Nature, 1987, 326, 883-885.	13.7	101
179	BF-1 Interferes with Transforming Growth Factor Î² Signaling by Associating with Smad Partners. Molecular and Cellular Biology, 2000, 20, 6201-6211.	1.1	94
180	Structural Basis for the Versatile Interactions of Smad7 with Regulator WW Domains in TGF-Î² Pathways. Structure, 2012, 20, 1726-1736.	1.6	93

#	Article	IF	Citations
181	TGFâ€Î² signaling in development and disease. FEBS Letters, 2012, 586, 1833-1833.	1.3	93
182	Breast cancer banishes p27 from nucleus. Nature Medicine, 2002, 8, 1076-1078.	15.2	91
183	Identifying Site-specific Metastasis Genes and Functions. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 149-158.	2.0	91
184	Genome-scale screens identify JNKâ€"JUN signaling as a barrier for pluripotency exit and endoderm differentiation. Nature Genetics, 2019, 51, 999-1010.	9.4	90
185	Platelets and metastasis revisited: a novel fatty link. Journal of Clinical Investigation, 2004, 114, 1691-1693.	3.9	87
186	Mad Upregulation and Id2 Repression Accompany Transforming Growth Factor (TGF)-Î²-mediated Epithelial Cell Growth Suppression. Journal of Biological Chemistry, 2003, 278, 35444-35450.	1.6	85
187	Extracellular matrix players in metastatic niches. EMBO Journal, 2012, 31, 254-256.	3.5	85
188	Inhibition of the Transforming Growth Factor Î²1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein. Journal of Biological Chemistry, 2000, 275, 40282-40287.	1.6	84
189	Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors. Nature Communications, 2017, 8, 2070.	5.8	81
190	Internalization of transforming growth factor-Î² and its receptor in BALB/c 3T3 fibroblasts. Journal of Cellular Physiology, 1986, 128, 216-222.	2.0	78
191	Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-Î² pathway and reveal microRNA regulation of TGFBR2. Silence: A Journal of RNA Regulation, 2011, 2, 3.	8.0	78
192	The insulin receptor: structural features. Trends in Biochemical Sciences, 1981, 6, 222-225.	3.7	73
193	A Very Private TGF-Î² Receptor Embrace. Molecular Cell, 2008, 29, 149-150.	4.5	73
194	Signaling Activity of Homologous and Heterologous Transforming Growth Factor-Î² Receptor Kinase Complexes. Journal of Biological Chemistry, 1995, 270, 7134-7141.	1.6	71
195	The transforming growth factors. Trends in Biochemical Sciences, 1985, 10, 237-240.	3.7	69
196	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell, 2019, 36, 402-417.e13.	7.7	69
197	<i><scp>RARRES</scp>3</i> suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Molecular Medicine, 2014, 6, 865-881.	3.3	65
198	Features of a Smad3 MH1-DNA Complex. Journal of Biological Chemistry, 2003, 278, 20327-20331.	1.6	64

#	Article	IF	Citations
199	Insulin control of rat hepatocyte glycogen synthase and phosphorylase in the absence of glucose. FEBS Letters, 1977, 82, 317-320.	1.3	62
200	Diverted Total Synthesis Leads to the Generation of Promising Cell-Migration Inhibitors for Treatment of Tumor Metastasis: In vivo and Mechanistic Studies on the Migrastatin Core Ether Analog. Journal of the American Chemical Society, 2010, 132, 3224-3228.	6.6	62
201	Structural basis for distinct roles of SMAD2 and SMAD3 in FOXH1 pioneer-directed TGF-Î² signaling. Genes and Development, 2019, 33, 1506-1524.	2.7	61
202	ID1 Mediates Escape from TGFÎ² Tumor Suppression in Pancreatic Cancer. Cancer Discovery, 2020, 10, 142-157.	7.7	59
203	Multiple type-? transforming growth factors and their receptors. Journal of Cellular Physiology, 1987, 133, 43-47.	2.0	57
204	Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. Molecular Cancer Research, 2022, 18, 599-611.	1.5	56
205	Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. Immunity, 2021, 54, 1037-1054.e7.	6.6	56
206	Platelets and metastasis revisited: a novel fatty link. Journal of Clinical Investigation, 2004, 114, 1691-1693.	3.9	55
207	Signalling change: signal transduction through the decades. Nature Reviews Molecular Cell Biology, 2013, 14, 393-398.	16.1	53
208	Understanding the molecular mechanisms driving metastasis. Molecular Oncology, 2017, 11, 3-4.	2.1	52
209	Transforming Growth Factor Receptor Gene TGFBR2 Maps to Human Chromosome Band 3p22. Genomics, 1994, 20, 114-115.	1.3	51
210	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.4	51
211	Multimodality imaging of TGFÎ² signaling in breast cancer metastases. FASEB Journal, 2009, 23, 2662-2672.	0.2	50
212	Crossing receptor boundaries. Nature, 1996, 382, 29-30.	13.7	49
213	Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. Cancer Research, 2015, 75, 3713-3719.	0.4	48
214	Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. ELife, 2019, 8, .	2.8	46
215	Interaction of Transforming Growth Factor-Î² Receptor I with Farnesyl-protein Transferase-Î± in Yeast and Mammalian Cells. Journal of Biological Chemistry, 1996, 271, 13931-13934.	1.6	44
216	HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBPÎ² Isoforms. Cancer Research, 2010, 70, 9927-9936.	0.4	44

#	Article	IF	Citations
217	Field Cancerization: Something New Under the Sun. Cell, 2012, 149, 1179-1181.	13.5	43
218	Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases. Nanoscale, 2017, 9, 1110-1119.	2.8	41
219	Wounding Smad. Nature Cell Biology, 1999, 1, E117-E119.	4.6	40
220	Ubiquitin removal in the TGF-Î² pathway. Nature Cell Biology, 2012, 14, 656-657.	4.6	37
221	Cyclin-dependent Kinase Inhibitors Uncouple Cell Cycle Progression from Mitochondrial Apoptotic Functions in DNA-damaged Cancer Cells. Journal of Biological Chemistry, 2005, 280, 32018-32025.	1.6	36
222	The inactivation of glycogen phosphorylase is not a prerequisite for the activation of liver glycogen synthase. FEBS Letters, 1979, 99, 321-324.	1.3	35
223	Dexamethasone Enhancement of Betaglycan (TGF-Î² Type III Receptor) Gene Expression in Osteoblast-like Cells. Experimental Cell Research, 1994, 211, 301-306.	1.2	33
224	Breast Cancer Tumor Size, Nodal Status, and Prognosis: Biology Trumps Anatomy. Journal of Clinical Oncology, 2011, 29, 2610-2612.	0.8	33
225	A helping hand from proteoglycans. Current Biology, 1991, 1, 117-119.	1.8	24
226	Targeting S100A9â€“ALDH1A1â€“Retinoic Acid Signaling to Suppress Brain Relapse in<i>EGFR</i>-Mutant Lung Cancer. Cancer Discovery, 2022, 12, 1002-1021.	7.7	22
227	Different Sensitivity of the Transforming Growth Factor-Î² Cell Cycle Arrest Pathway to c-Myc and MDM-2. Journal of Biological Chemistry, 2000, 275, 32066-32070.	1.6	20
228	Negative regulators of growth. Current Opinion in Genetics and Development, 1992, 2, 28-32.	1.5	18
229	Opposite Smad and Chicken Ovalbumin Upstream Promoter Transcription Factor Inputs in the Regulation of the Collagen VII Gene Promoter by Transforming Growth Factor-Î². Journal of Biological Chemistry, 2004, 279, 23759-23765.	1.6	18
230	Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. Journal of Neuro-Oncology, 2012, 109, 229-238.	1.4	17
231	H3K18ac Primes Mesendodermal Differentiation upon Nodal Signaling. Stem Cell Reports, 2019, 13, 642-656.	2.3	16
232	Arresting supporters: targeting neutrophils in metastasis. Cell Research, 2016, 26, 273-274.	5.7	15
233	[14] Affinity cross-linking of receptors for insulin and the insulin-like growth factors I and II. Methods in Enzymology, 1985, 109, 179-187.	0.4	13
234	Multiple phosphorylation of rabbit muscle glycogen synthase by glycogen synthase kinase-1. FEBS Letters, 1979, 106, 279-283.	1.3	12

#	Article	IF	Citations
235	Transforming growth factor-Î±. Biochemical Society Transactions, 1991, 19, 259-262.	1.6	11
236	Cell multiplication. Current Opinion in Cell Biology, 1995, 7, 769-772.	2.6	11
237	Mechanisms in TGFâ€Î² Action. Novartis Foundation Symposium, 1991, 157, 51-65.	1.2	11
238	Modulation of type Î± transforming growth factor receptors by a phorbol ester tumor promoter. Journal of Cellular Biochemistry, 1985, 27, 23-30.	1.2	8
239	[13] Identification of receptor proteins for type-Î± transforming growth factor. Methods in Enzymology, 1987, 146, 143-153.	0.4	8
240	Anti-tumor effects of an ID antagonist with no observed acquired resistance. Npj Breast Cancer, 2021, 7, 58.	2.3	8
241	TIF1Î³ Knockdown Enhances Hematopoietic Stem Cell Self Renewal with Preferential Myeloid Differentiation and Delayed Erythropoiesis. Blood, 2011, 118, 4829-4829.	0.6	8
242	Hypoxia Signalingâ€"License to Metastasize. Cancer Discovery, 2013, 3, 1103-1104.	7.7	7
243	The transcription factor Rreb1 regulates epithelial architecture, invasiveness, and vasculogenesis in early mouse embryos. ELife, 2021, 10, .	2.8	7
244	Cell regulation. Current Opinion in Cell Biology, 2008, 20, 117-118.	2.6	5
245	Invasion and Metastasis. , 2015, , 269-284.e2.		5
246	BF-1 Interferes with Transforming Growth Factor Î² Signaling by Associating with Smad Partners. Molecular and Cellular Biology, 2000, 20, 6201-6211.	1.1	5
247	Networks of tumor suppressors. EMBO Reports, 2000, 1, 115-119.	2.0	4
248	STRUCTURAL FEATURES OF THE INSULIN EFFECTOR SYSTEM: RELATION TO HEXOSE TRANSPORT ACTIVATION. Annals of the New York Academy of Sciences, 1980, 358, 282-291.	1.8	3
249	[10] Purification of type-Î± transforming growth factor from transformed cells. Methods in Enzymology, 1987, 146, 103-112.	0.4	3
250	Labeling and Isolation of Fluorouracil Tagged RNA by Cytosine Deaminase Expression. Bio-protocol, 2019, 9, e3433.	0.2	2
251	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. Neuro-Oncology Advances, 2020, 2, ii10-ii11.	0.4	0
252	Kathryn Anderson, grand dame of developmental biology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2101148118.	3.3	0

#	Article	IF	Citations
253	Immunostaining Protocol: P-Stat3 (Xenograft and Mice). Bio-protocol, 2014, 4, .	0.2	0